Clinical Trial Update: A Phase 1-2, XIAP Antisense AEG35156 With Weekly Paclitaxel in Patients With Advanced Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1-2 trial of XIAP antisense AEG35156 with weekly paclitaxel in advanced breast cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• AEG35156 (XIAP antisense oligonucleotide)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Aegera Therapeutics | Conditions: Human Mammary Carcinoma | Phase 1, Phase 2 | Status: TERMINATED